Ascentage Pharma Group International ASPHF
3.46 USD 0.00 (+0.00%)
At closeNov 9, 2026, 4:00 PM EST
3.46 Day range 3.46
3.46 52-week range 9.32
- YTD
- -59.20%
- 1 year
- -62.88%
News
seekingalpha.com Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript Ascentage Pharma Group International (AAPG) Q4 2025 Earnings Call Transcript
seekingalpha.com Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript Ascentage Pharma Group International (AAPG) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
defenseworld.net Ascentage Pharma Group International (OTCMKTS:ASPHF) Sees Significant Increase in Short Interest Ascentage Pharma Group International (OTCMKTS:ASPHF - Get Free Report) saw a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling…
seekingalpha.com Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Ascentage Pharma Group International (AAPG) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
defenseworld.net Ascentage Pharma Group International (OTCMKTS:ASPHF) Stock Price Down 23.4% – Should You Sell? Ascentage Pharma Group International (OTCMKTS:ASPHF - Get Free Report)'s stock price fell 23.4% on Tuesday. The company traded as low as $7.50 and last traded at $7.7350. 3,556 shares were traded…
defenseworld.net Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Update Ascentage Pharma Group International - Unsponsored ADR (NASDAQ: AAPG - Get Free Report) saw a significant decline in short interest in the month of October. As of October 15th, there was short…
seekingalpha.com Ascentage Pharma Group International (AAPG) Presents At Citi's Biopharma Back To School Conference Transcript Ascentage Pharma Group International (NASDAQ:AAPG ) Citi's Biopharma Back to School Conference September 3, 2025 4:00 PM EDT Company Participants Veet Misra - Chief Financial Officer Conference Call…
reuters.com Takeda-backed Ascentage Pharma aims to raise $126 mln in US IPO Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.
reuters.com Takeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPO China-based Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering in the United States.
prnewswire.com Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference ROCKVILLE, Md. and SUZHOU, China , Dec. 26, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax ROCKVILLE, Md. and SUZHOU, China , Dec. 10, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors ROCKVILLE, Md. and SUZHOU, China , Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to…
prnewswire.com Ascentage Pharma Announces a New Drug Application for Its Novel Bcl-2 Inhibitor Lisaftoclax Accepted and Recommended Priority Review Designation by CDE of China NMPA ROCKVILLE, Md. and SUZHOU, China , Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to…
prnewswire.com ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report ROCKVILLE, Md. and SUZHOU, China , Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com ASH 2024 | Results From Three Clinical Studies of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax Selected for Presentations, Including an Oral Report ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to…
prnewswire.com Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation ROCKVILLE, Md. and SUZHOU, China , Sept.
prnewswire.com ESMO 2024 | Ascentage Pharma to Present Updated Data of Olverembatinib in Patients with SDH-Deficient GIST during a Mini Oral Presentation at the 2024 ESMO Congress ROCKVILLE, Md. and SUZHOU, China , Sept.
prnewswire.com Ascentage Pharma Announces 2024 Interim Results ROCKVILLE, Md. and SUZHOU, China , Aug. 22, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing both…